The global animal vaccine market size was USD 15.70 billion in 2023, calculated at USD 17.27 billion in 2024 and is projected to surpass around USD 44.79 billion by 2034, expanding at a CAGR of 10% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Animal Vaccine Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Animal Vaccine Market Revenue and Volume Forecast, by Product Type, 2023-2032
8.1.1. Attenuated Live Vaccines
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Inactivated Vaccines
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Subunit Vaccines
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. DNA Vaccines
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. Recombinant Vaccines
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
9.1. Animal Vaccine Market Revenue and Volume Forecast, by Animal Type, 2023-2032
9.1.1. Livestock
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Companion
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1. Animal Vaccine Market Revenue and Volume Forecast, by Route of Administration, 2023-2032
10.1.1. Subcutaneous
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Intramuscular
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1.3. Intranasal
10.1.3.1. Market Revenue and Volume Forecast (2020-2032)
11.1. Animal Vaccine Market Revenue and Volume Forecast, by End User, 2023-2032
11.1.1. Hospital
11.1.1.1. Market Revenue and Volume Forecast (2020-2032)
11.1.2. clinics
11.1.2.1. Market Revenue and Volume Forecast (2020-2032)
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.1.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.1.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.1.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.1.5.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.1.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.1.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.1.6.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.1.6.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.1.6.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.2.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.2.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.2.5.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.2.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.2.6.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.2.6.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.6.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.2.7.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.2.7.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.7.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.2.8.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.2.8.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.8.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.3.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.3.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.3.5.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.3.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.3.6.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.3.6.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.6.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.3.7.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.3.7.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.7.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.3.8.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.3.8.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.8.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.4.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.4.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.4.5.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.4.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.4.6.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.4.6.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.6.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.4.7.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.4.7.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.7.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.4.8.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.4.8.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.8.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.5.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.5.5.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.5.5.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.5.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Product Type (2020-2032)
12.5.6.2. Market Revenue and Volume Forecast, by Animal Type (2020-2032)
12.5.6.3. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.5.6.4. Market Revenue and Volume Forecast, by End User (2020-2032)
13.1. Merck & Co., Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Zoetis
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Boehringer Ingelheim International GmbH
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Virbac
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Biogénesis Bagó
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Indian Immunologicals Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Elanco
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Ceva
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Phibro Animal Health Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Neogen Corporation
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample